Last reviewed · How we verify
Sodium Oligomannate Capsules
Sodium oligomannate modulates the gut microbiota and reduces neuroinflammation by altering bacterial composition and metabolite production.
Sodium oligomannate modulates the gut microbiota and reduces neuroinflammation by altering bacterial composition and metabolite production. Used for Mild to moderate Alzheimer's disease.
At a glance
| Generic name | Sodium Oligomannate Capsules |
|---|---|
| Sponsor | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. |
| Drug class | Prebiotic oligosaccharide |
| Target | Gut microbiota (indirect); short-chain fatty acid signaling |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Sodium oligomannate is a prebiotic oligosaccharide that selectively promotes the growth of beneficial bacteria in the gut microbiota, particularly Faecalibacterium prausnitzii. This shifts the microbial ecosystem away from pathogenic species and increases the production of short-chain fatty acids, which cross the blood-brain barrier and reduce neuroinflammatory responses implicated in neurodegeneration.
Approved indications
- Mild to moderate Alzheimer's disease
Common side effects
- Gastrointestinal disturbance
- Diarrhea
- Abdominal discomfort
Key clinical trials
- Efficacy and Safety of Sodium Oligomannate in the Prevention of PSCI (NA)
- A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) (PHASE4)
- Long-term Efficacy and Safety Study of GV-971 (PHASE4)
- Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: